Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests by Stone, Christine et al.
Deakin Research Online 
 
This is the published version:  
 
Stone, Christine, Carter, Robert, Vos, Theo and St John, James 2004, 
Colorectal cancer screening in Australia: an economic evaluation of a 
potential biennial screening program using faecal occult blood tests, 
Australian and New Zealand journal of public health, vol. 28, no. 3, pp. 
273-282.  
 









Copyright : 2004, Public Health Association of Australia 
2004 VOL. 28 NO. 3 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH 273
Colorectal cancer screening in Australia:
An economic evaluation of a potential biennial
screening program using faecal occult blood tests
Christine A. Stone
Public Health Group, Rural & Regional Health & Aged Care Services,
Department of Human Services, Victoria
Robert C. Carter
Health Economics Group and Program Evaluation Unit, School of Population
Health, The University of Melbourne, Victoria
Theo Vos
School of Population Health, University of Queensland
James St John
National Cancer Control Initiative, Victoria
Abstract
Objective: To evaluate whether the
introduction of a national, co-ordinated
screening program using the faecal occult
blood test represents ‘value-for-money’ from
the perspective of the Australian
Government as third-party funder.
Methods: The annual equivalent costs and
consequences of a biennial screening
program in ‘steady-state’ operation were
estimated for the Australian population
using 1996 as the reference year. Disability-
adjusted life years (DALYs) and the years of
life lost (YLLs) averted, and the health
service costs were modelled, based on the
epidemiology and the costs of colorectal
cancer in Australia together with the
mortality reduction achieved in randomised
controlled trials. Uncertainty in the model
was examined using Monte Carlo
simulation methods.
Results: We estimate a minimum or ‘base
program’ of screening those aged 55 to 69
years could avert 250 deaths per annum
(95% uncertainty interval 99-400), at a
gross cost of $A55 million (95% UI $A46
million to $A96 million) and a gross
incremental cost-effectiveness ratio of
$A17,000/DALY (95% UI $A13,000/DALY to
$A52,000/DALY). Extending the program to
include 70 to 74-year-olds is a more
effective option (cheaper and higher health
gain) than including the 50 to 54-year-olds.
Conclusions: The findings of this study
support the case for a national program
directed at the 55 to 69-year-old age group
with extension to 70 to 74-year-olds if there
are sufficient resources. The pilot tests
recently announced in Australia provide an
important opportunity to consider the age
range for screening and the sources of
uncertainty, identified in the modelled
evaluation, to assist decisions on
implementing a full national program.
(Aust N Z J Public Health 2004; 28: 273-82)
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1. In 2003, this population estimate is 20
million people. The reported incidence of CRC
is 12,405 and deaths of 4,718 in 2000.3
Article Health Promotion and Disease Prevention
C olorectal cancer (CRC) is thefourth commonest cancer worldwide.1 Australia’s incidence and
mortality rates rank among the highest in the
world.2 In a population of 18 million in 1996
(see footnote), it was the second most promi-
nent cancer with more than 11,000 new cases
and almost 5,000 deaths.2 These new cases
and deaths were responsible for 67,000 dis-
ability-adjusted life years (DALYs) or 15%
of the total burden of disease due to all can-
cers in 1996.4 Total health system costs as-
sociated with CRC were approximately $205
million in 1993/94.5
A meta-analysis of four randomised con-
trolled trials (RCTs) of biennial population
screening using the faecal occult blood test
(FOBT) has shown it to be efficacious in
reducing the risk of mortality by 16%.6 Ac-
ceptability was high with an average partici-
pation rate of 66%.6 Mathematical
simulation studies have demonstrated that
the cost-effectiveness of such a program
would be similar or even better than the cur-
rent breast and cervical screening programs
in the US, Denmark, the UK and Australia.7-
10 On the basis of these results, screening of
asymptomatic individuals, starting at the age
of 50 years, is recommended and national
programs are under consideration in a
number of countries.11,12 Australia com-
menced pilot screening programs in three
States: Queensland (November 2002) and
Victoria and South Australia (early 2003).
As part of a larger priority setting study13,14
commissioned by the Cancer Strategy
Group, an advisory body of the Australian
Government, an economic evaluation was
undertaken to assess the economic creden-
tials of introducing a national CRC screen-
ing program. Annual and biennial screening
programs, targeting different age groups,
were evaluated compared with the status quo.
This paper describes the details of the evalu-
ation of the biennial program because of the
stronger evidence of efficacy (four RCTs as
opposed to one RCT) and the better eco-
nomic credentials.
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Table 1: Comparison of status quo and proposed national program.
Program components Status quo National program
Infrastructure Opportunistic program, no formal structure National recruitment campaign, co-ordination
of recruitment, co-ordination and registry. and registry.
Screening by FOBT – includes the kit, Small local programs offered on an ad hoc Targeted general practice delivered program
transport, processing, GP visit. basis to the general public by volunteer similar to the Australian cervical cancer
organisations. screening program.
Minimal participation rate around 2%. Biennial program.
Participation rate in RCT was 66%, which
equates to 33% per annum.
Screening by colonoscopy. Assume 15% of current colonoscopies are Assume the de facto screening colonoscopies
de facto screening colonoscopies. reduce due to introduction of a national
program.
Diagnostic work-up – includes a colonoscopy Diagnostic work-up of individuals with Diagnostic work-up of individuals with
and an initial and follow-up specialist visit. positive FOBT. positive FOBT.
Small number of screen-induced diagnostic Assume all positive FOBT are followed up,
work-up. rate dependent on the positivity of the FOBT
detection method.
Treatment (stage specific). Based on current stage distribution. Shift to earlier stage at diagnosis.
Shift in stage distribution predicted by
modelling based on mortality reduction
achieved in RCTs.
Palliation. For non-survivors predicted by stage-specific For non-survivors predicted by stage-specific
five-year survival rates. five-year survival rates.
Follow-up surveillance – by repeat Small number of screen-induced Assume 25% of those with a positive FOBT
diagnostic work-up in 3-5 years. surveillance follow-up. will have a polyp >10mm and will be followed
up according to guidelines.
Complications of colonoscopy. Perforation and mortality. Perforation and mortality.
These will increase with an increase in
colonoscopies.
2. The generic term of cost-effectiveness analysis is used to include
the cost-utility analysis ($/DALY) and cost-effectiveness ($/YLL), as
adopted by the Washington Panel.30
3. ‘Average risk’ in this case corresponds to asymptomatic
individuals above the age of 50 years with no family history of
colorectal cancer and no other special risk factors; it also includes at
a slightly higher risk of up to double the average, individuals with
one first-degree relative diagnosed with CRC above the age of 55
years.
Stone et al. Article
Methods
The evaluation
The annual equivalent benefits, costs and cost-effectiveness of
a national CRC program were modelled and compared with the
status quo using a cost-effectiveness analysis (see footnote 2).
The evaluation assumed a hypothetical, nationally co-ordinated
screening program, using a standard guaiac-based test for faecal
occult blood test (FOBT) equivalent to those used in the RCTs,
and delivered biennially to the Australian population of 1996 for
those of ‘average risk’ (see footnote 3).15 It also was assumed the
program was in ‘steady state’ in order to represent the annual
ongoing cost and consequences of the screening program deliv-
ered in 1996. This excludes the increase in detection of cancers
and higher implementation costs early after the introduction of a
program.
Based on a preliminary analysis, screening 55 to 69-year-olds
was considered the minimum or ‘base program’ from an economic
point of view. Extension of the program to younger and older age
groups was also evaluated using marginal analysis. The compara-
tor was the status quo of minimal opportunistic screening by FOBT
(2%, expert opinion) and some de facto screening by colonoscopy
(Victorian inpatient data). Table 1 provides a comparison of the
main components of the status quo and the proposed program.
The perspective used was that of the Australian Government as
third-party funder of such a program. A Working Party of the
Cancer Strategies Group (CSG), comprising cancer experts, gov-
ernment policy makers and a consumer representative, was set up
to advise and support the project. The CSG Working Party and
DJB StJ provided the ‘expert opinion’ when there was no pub-
lished evidence available and/or when the overseas evidence
needed modification for the local context.
Health benefits
The health benefit was estimated in DALYs, which combines
mortality, measured as years of life lost (YLLs) and morbidity,
measured as years lived with disability (YLDs). The estimated
change in DALYs in the presence of the hypothetical screening
program is equal to the sum of the estimated change in the YLLs
and the YLDs associated with CRC. The methodology used in
Burden of Disease (BOD) studies4,16,17 was adapted for this
study.13,14 Consistent with the previous BOD studies, all future
health benefits and costs were discounted at 3% (see footnote 4)
to indicate a time preference for delaying costs and having health
benefits now rather than in the future.
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Figure 1: Colorectal cancer
disease model showing different
phases for survivors and
non-survivors.
4. Consistent with PBAC and NHMRC, a discount rate of 5% was
also modelled with no difference on final results.
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The YLD estimations
Figure 1 shows the single disease-based model used to esti-
mate the YLDs associated with each phase of CRC for survivors
and non-survivors in the Australian Burden of Disease and Injury
study.4 For our study, a separate model was used for each of the
CRC Duke’s stages A to D. Incident cases were allocated to one
of the four stage-models according to the current and predicted
distribution of the stages. The proportions of survivors and non-
survivors were based on five-year, stage-specific survival rates.18
The YLDs were calculated as the product of incidence and aver-
age duration of the health state weighted for severity expressed in
disability weights (DW)19 as a proportion between 0 (full health)
and 1 (worst possible health state).
The YLL estimations
The original BOD studies used observed incidence and mortal-
ity from which to calculate YLLs. In our study the number of deaths,
and hence YLLs, were modelled from predicted mortality based on
the five-year survival rate. For each death averted (or increase in
survivors from the model), the YLLs recovered was estimated from
the difference between the discounted life expectancy for that age-
group and the discounted mean survival time for CRC patients in
each age group. The Australian 1996 Cohort Life Expectancy was
used as a standard against which YLLs were calculated. 4
Epidemiological parameters used in the model
National data were used for cancer incidence, mortality, age of
onset, mean survival time for each age group, and duration asso-
ciated with each phase of the model for survivors and non-survi-
vors.2,4 Data from the South Australian Cancer Registry provided
the stage distribution and five-year survival rates.18 The distribu-
tion of patients in stages A to D, at time of diagnosis
(0.14 : 0.33 : 0.31 : 0.21) was close to the combined distributions
in the control groups from the RCTs. On advice from the CSG
Working Party the five-year survival rates from each stage, which
were an average over 15 years of data, were increased by 5% to
reflect current improved survival rates (92%: 75%: 44%: 5%).
Based on a meta-analysis of three of the randomised controlled
trials,20-22 in the presence of a screening program, it was assumed
that the CRC incidence would be unchanged but the mortality
rate would fall by 14%. A CRC stage shift from status quo to
0.26 : 0.28 : 0.32 : 0.15 (coincidentally similar to the stage distri-
bution achieved in the Swedish study)21 achieved this mortality
reduction in our model. The fourth randomised controlled trial,
the Minnesota study,23 was excluded because the high positivity
rate of their FOBT – almost 10% – resulted in 28% of the sub-
jects having one or more colonoscopies.
Health service utilisation, costs and assumptions
The main health service utilisation assumptions used in the
model and the sensitivity analysis are summarised in Table 2.
Estimates of the total health care utilisation and the gross and net
costs were modelled in Excel for the proposed screening pro-
gram and compared with the status quo comparator.
Table 3 shows the screening pathway comparing the health serv-
ices, their costs and the resource utilisation for the status quo
situation and in the presence of the proposed program directed at
those aged 55 to 69-years-old. Gross costs (screening program
costs only) included the infrastructure, FOBT screens, diagnostic
work-up and the cost of complications arising from the diagnos-
tic procedures resulting from the screening program. Net costs
276 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH 2004 VOL. 28 NO. 3
Table 2: Assumptions used in the primary analysis and in the sensitivity analysis.
Variable Primary analysis Sensitivity analysis Rationale for distribution
Current rate of opportunistic 2% Triangular distribution from 0.015 2%,23 expert opinion
FOBT screening peaking at 0.03 and ending at 0.07 5%39
Participation ratea with 66% i.e. 33% per annum Triangular distribution from 40%, 66%6
proposed biennial screening peaking at 66% and ending at 82% 50%39
program 40% to 82% CSG working party
FOBT positivity rate/ 2% Triangular distribution from 0.015 2% 20,22
colonoscopy rateb peaking at 0.03 and ending at 0.07 5%39
Deaths from colonoscopies 2/10,000 Uniform distribution from 1 and 3 0.2%15
per 10,000
De facto screening 15% Uniform distribution between 0% Calculated from inpatient data
colonoscopies and 15%
Follow-up surveillance 25% Triangular distribution from 7%, 25%;40 expert opinion
of polypsc peaking at 20% and ending at 30%
Program / $1996 $7.9 million Uniform distribution of reported Consistent with other cost variation
costs +/-10%
Costs of colonoscopy $1,000 Uniform distribution of reported Costs were fairly consistent from
costs +/-20% Australian reports but vary widely if public
or private sector.
Other costs As stated in assumptions Uniform distribution of reported Costs were fairly consistent from
in Table 3 costs +/-10% Australian reports but vary if public or
private sector.
Mortality (biennial) reduction 14% Normal distribution (mean 13, SD 3.6) Modification of modelled change in
mortality with CI from literature6
Disability weight uncertainty Refer Figure 1 Uniform distribution from 0.5 to twice Expert opinion
the disability weight for Dx, remission
or ‘cured’ phases of CRC
Notes:
(a) Assumed to be constant across all age groups.
(b) Assumed all positive FOBT are followed up with a colonoscopy.
(c) Approximately 25% of individuals with positive FOBT have a polyp (adenoma) greater than 10mm20,22 that should be followed up.
Table 3: The health service cost and resource utilisation for base program (55-69-year-olds).
Screening pathway Service Unit Unit cost Status quo Proposed biennial
$1996a (no. of screening
units) program
(no. of units)
1. Infrastructure Recruitment, co-ordination Program 7.9 millionb 0 1
and registry
2. Screens FOBT kit, transport, Screen 4141,42 45,000 740,000
processing, GP visit
3. De facto screening Colonoscopyc Colonoscopy 1,00043 11,000
colonosopies
4. Diagnostic work-up Colonoscopyc Pos FOBT 1,00043 900 15,000
Initial visit + follow up Pos FOBT 17638,41 900 15,000
5. Complications Perforation 0.0017 per 15,00038 19 25
colonoscopy15
6. Treatment Dukes A (surgery) Stage specific 14,00038 570 1,000
Dukes B (surgery) Stage specific 14,00038 1,300 1,100
Dukes C (surgery + Stage specific 22,00038 1,200 1,200
adjuvant chemotherapy)
Dukes D (palliative Stage specific 19,00038 800 600
chemotherapy + surgery)
7. Palliation Advanced Mortality 25,0009 1,900 1,600
8. Follow-up surveillance Diagnostic work-up see 25% positive 880d 38,41 3,000 4,000
above but in 3-5 years’ time FOBT
Notes:
(a) All costs are presented in real prices for the 1996 reference year with future costs discounted to present value at 3% per annum.44
(b) Commonwealth screening program (personal communication, 2000).
(c) Colonoscopy includes immediate complications such as haemorrhage, and full hospital costs (not just medical fee for procedure).
(d) Costs incurred on average in four years’ time therefore discounted back to 1996.
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Table 4: Incremental cost analysis – point estimates (PE) and lower and upper limits (LL,UL) of the uncertainty
intervals of health benefits, costs and cost-effectiveness ratios for biennial screening for colorectal cancer in
Australia, 1996.
Extension to Extension to Base program Extension to Extension to
include include include include
Age group (years) 45-49 50-54 55-69a 70-74 75+
PE LL UL PE LL UL PE LL UL PE LL UL PE LL UL
Health benefit
Deaths 26  8.0  39 42 16 65 250 99  400  120 50 200 200 81 320
YLLs 490 150  750 730 270 1100  3,200  1,300 5,000 1,100 440  1,700  1,400  560  2,200
DALYs 490 150  750 730 270 1100  3,200  1,200 5,000 1,100 430  1,700  1,300  510  2,200
Costs ($m)
Gross costs 27  22  51 22 18 40 55 46 96  13 10 24 19 16 36
Net costs 25  21  54 18 15 41 39 33 92 5.7  4.5 21  8.8  6.8 31
ICER
Gross costs  56,000  42,000  216,000  29,000 22,000 97,000  17,000 13,000 52,000  12,000  9,000  36,000 15,000 11,000 46,000
/DALY
Gross costs  56,000  42,000  216,000  29,000 22,000 97,000  17,000 13,000 52,000  12,000  8,900  35,000 14,000 10,000 42,000
/YLL
Net costs  50,000  40,000  223,000  24,000 20,000 96,000  12,000 10,000 47,000 5,300  4,500  29,000  6,600 5,500 35,000
/DALY
Net costs  50,000  40,000  226,000  24,000 20,000 97,000  12,000 10,000 47,000 5,300  4,500  28,000  6,400 5,400 33,000
/YLL
Notes:
(a) The base program includes infrastructure costs of $7.9 million.
Figures have been rounded to two significant digits.30
The results for the ‘extension’ programs are incremental results to the base program and do not show results for the combined (base + extension) program.
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included projected treatment savings, savings from reduced
de facto screening by colonoscopy, and the additional expense
anticipated from increased follow-up activity.
Infrastructure costs were allocated to the base program on the
assumption that costs would not change greatly with the inclu-
sion of other age groups into the screening program. Costs fall-
ing on participants were not included.
Sensitivity analysis
A multiway probabilistic sensitivity analysis was performed
using @RISK software.24 The input uncertainty distributions were
based on a combination of the reported confidence intervals for
that variable, the range of reported values in the literature and
expert opinion on the range of likely values under Australian con-
ditions (see Table 2). The output distributions reported are the 2.5
(lower limit) and 97.5 (upper limit) percentiles of the 2000 Monte
Carlo simulations because of their skewed distribution. This
skewed distribution occurred as four of the input variables had a
skewed distribution (see Table 2). In addition, the @RISK soft-
ware identifies major influential factors and the input uncertainty
distributions that have the greatest impact on the results by re-
gression and correlation of inputs and outputs for each of the
iterations of the simulation.
Results
The costs, benefits and cost-effectiveness of the base program,
together with the incremental costs of screening additional age
groups, are summarised in Table 4. The results are expressed as
cost (Australian dollars) per YLL avoided, as well as cost per DALY
avoided, to enable comparison with published cost-effectiveness
and cost-utility studies.
Benefits, costs and incremental cost-effectiveness
ratios (ICER=∆C/∆E)
A base program (screening 55 to 69-year-olds) would have pre-
vented 250 deaths and avoided 3,200 DALYs due to CRC in 1996.
Extension to the older age groups (70 to 74 years, or 70 years and
over) would have avoided significantly more DALYs than addi-
tion of younger age groups (50 to 54 years or 45 to 54 years).
The gross annual cost of the base program in 1996 would have
been $55 million, including infrastructure costs of $7.9 million.
Inclusion of anticipated treatment savings from less advanced
disease ($7.6 million), plus savings from a reduction in de facto
screening colonoscopies ($13 million), offset by additional costs
of follow-up surveillance ($4.3 million) produces a net annual
cost of $39 million. Addition of the older age groups would cost
significantly less than addition of the younger age groups.
The ICER of the base program would be $17,000/DALY (gross)
or $12,000/DALY (net) and is even better for the older age groups.
Extending the program to include 50 to 54-year-olds would in-
crease benefits, but at a substantial cost of $29,000/DALY gross
($24,000/DALY net), which amounts to almost double the cost
per DALY of the baseline program.
Sensitivity analysis
For the base program the point estimate for the number of deaths
avoided is 250, with lower and upper limits of 99 and 400. The















Figure 2: Point estimates and 95% uncertainty intervals
of the cost-effectiveness ratio.
The point estimate, indicated by the square block, provides an estimate of
the ICER under ideal conditions whereas the 95% uncertainty intervals,
based on Monte Carlo simulation, provide an indication of the range of
expected values in the Australian context.
Table 5: Previous economic evaluations on colorectal cancer (CRC) screening using FOBT.
Paper Cost per LYSa ($1996)b Comments
England 198927 $8,000 Mathematical models
Eddy 199037 $15,000 Markov Model, 50-year-old cohort, annual FOBT, 100% compliance
Tsuji 199145 $29,000 Compared with ‘no screen’, some direct costs to patients
Byers 199246 $14,000 Markov model (Eddy), expert opinion, uncontrolled screening studies
Shimbo 199432 $30,000 (B), $14,000 (I) Compared immunological (I) with biochemical (B), 40-year-old cohort,
100% compliance
Wagner (OTA 1990) 199125 $56,000 Markov model, comparator ‘no screen’
Brown 199347 $44,000 Eddy’s Markov model, Mandel impact figures, comparator controls
from trial
Salkeld 19969 $26,000 Mandel, comparator ‘no screen’, annual FOBT, Minnesota study
population, 50 to 80 years
Wagner 199626 $19,000, $14,000 Eddy’s Markov model, comparator ‘no screen’, annual FOBT
Gyrd-Hansen 19988 $2,700-$6,600 Day and Walter model, Kronborg data, comparator ‘no screen’, costs
and incremental costs, biennial and annual, many age groups
Bolin 199938 $36,000 annual Markov model (based on the OTA), 50-year-old cohort, 100%
$33,000 biennial compliance
Frazier 20007 $32,000 Markov model, no screen comparator, 50-year-old cohort US
population, annual FOBT
Helm 200028 $26,000, $3,400, $3,200 Deterministic model, Mandel, Kronberg and Hardcastle data, US
population 45-75 years, 60% compliance
Khandker 200029 $21,000 State transition model, 50-year-old cohort, annual FOBT,
100% compliance
Sonnenberg 200048 $11,000 (1) Markov model, 50-year-old cohort, comparator ‘no screen’, annual
$26,000 (2) FOBT, (1) 100% compliance, (2) 66% compliance
Vijan 200149 $9,000 Markov model, 50-year-old cohort, comparator ‘no screen’, annual
FOBT, 75% compliance
Cost per QALY
Whynes 199810 Males: $5,000-$11,000 Model, Hardcastle data, NHS
Females: $2,800-$10,000 comparator breast cancer, incremental
5 simulations 1) trial; 2) K population; 3) + lifetime costs; 4) change
compliance at screen 4; 5) high initial compliance
Notes:
(a) Cost per life year saved is equivalent to cost per year of life lost ‘saved’ – all figures are rounded to two significant digits.
(b) Conversions to Australian dollars were done using purchasing power parities.50
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gross costs may be as low as $46 million or as high as $96 mil-
lion. The corresponding ICER range from a low of $13,000/DALY
to a high of $52,000/DALY (see Table 4).
If $50,000/DALY were acceptable to the policy makers as a
threshold value for the ICER, then biennial screening of the 55 to
69 age group, with extension to the 70 to 74 age group and ulti-
mately the 75 and over age group, should be cost-effective (see
Figure 2). The probability that the 50 to 54 age group would meet
this threshold are significantly lower, with the 45 to 49 age group
weaker still.
The major influences on the uncertainty of the health benefits
were the size of the mortality reduction and the screening partici-
pation rate. The FOBT positivity and the participation rates have
greatest bearing on the cost estimates. The major influences on the
uncertainty of the ICER are the size of the mortality reduction and
the FOBT positivity rate. Other influences are the participation rate
and the expected reduction in the number of de facto screening
colonoscopies due to the presence of a screening program.
Comparison with other economic studies
Previous economic evaluations of screening using FOBT are
outlined in Table 5. Their ICERs range from $3,000/LYS to
$56,000/LYS in $A1996 and most are reporting net costs. Our
result of $17,000/YLL (gross) (see footnote 5) or $12,000/YLL
(net) is at the lower end of the spectrum. This is not surprising.
First, we have modelled the program in steady-state operation,
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Table 6: Cost-effectiveness of primary prevention programs using same economic protocol.13,14
Interventions Annual cost DALYs saved (lost) Cost per DALYa
(savings) per year
Increments $ millions Point Lower Upper
National Tobacco Campaign
Gross costs (no offsets) 9.0 11,000 840 540 1,200
Net costs (or net saving) (39) Dominant Dominant Dominant
National SunSmart Program
Gross costs (no offsets) 2.5 10,000 250 240 500
Net costs (or net saving) (37) Dominant Dominant Dominant
National Fruit and Vegetables Campaign
Gross costs (no offsets) 2.5 3,600 680 510 16,000
Net costs (or net saving) (12) Dominant Dominant Dominant
Note:
(a) The net cost per DALY estimates provided include the point estimate (i.e. the result from the primary economic analysis) together with the upper and lower bound
estimates from the sensitivity analysis.
5. Note we are using the YLL component of the DALY only in this
comparison, as the studies being assessed did not include a
morbidity measure in their evaluations.
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excluding the more costly start-up and implementation period.
Second, many have modelled the cost and consequences for a
cohort of 50-year-olds using mathematical simulation methods.
Our analysis has demonstrated that including the 50-to-54-year-
olds will increase the average cost/YLL. Third, early studies have
used data from the Minnesota study, which has a high positivity
rate resulting in higher cost and cost per benefit ratio. Fourth, we
report here a biennial screening program. Application of our model
to an annual screening population resulted in a higher health ben-
efit (400 deaths averted and a reduction of 5,000 DALYs), at higher
costs of $100 million gross, resulting in a higher ICER of $20,000/
DALY. Finally, they have also included different costs and cost
offsets in addition to the costs of the basic screening program.
Our analysis shows the ICER differs for gross and net costs par-
ticularly in the older age groups.
Our range of ICERs from the sensitivity analysis, for biennial
screening, of $13,000/YLL to $52,000/YLL (gross) and $10,000/
YLL to $47,000/YLL (net) includes most of the reported ICERs.
Only one study had a higher ICER ($56,000/LYS),25 which has
since been revised to $14,000/LYS and $19,000/LYS.26 Whereas
four studies had more favourable ICERs ranging from $2,700/
LYS to $9,000/LYS.8,27-29 The only study to report a utility meas-
ure reported an ICER of $2,800/QALY to $11,500/QALY.10
Discussion
Our study is noteworthy in its use of the DALYs as an outcome
measure. The use of DALYs in evaluation studies, as opposed to
burden of disease descriptions, is in its infancy. The DALY, by
combining mortality and morbidity in a single measure, has the
potential to enable comparisons across a range of interventions.
Indeed, comparisons were made between divergent interventions
applied across the cancer continuum from prevention to psycho-
social care as part of the larger priority-setting exercise with good
response from those involved in cancer control.13,14 There has only
been one previous study to our knowledge that has used a similar
measure, the QALY, in an evaluation of FOBT screening for
CRC.10 Both DALYs and YLLs are reported here to allow direct
comparison with other economic studies that have used life-years
saved, which are reported to be a standard and more reliably meas-
ured health benefit.30 Part of that concern is the reliability of the
disability weight and the estimation of the YLDs. For this inter-
vention, the contribution of the YLDs to the numerical value of
the DALYs is so small that the DALY value is almost equivalent
to the YLL value.
In the presence of scarce resources, a sensible decision-making
process entails starting with a minimum or base program and then
giving consideration to expansion to include various design com-
binations using marginal analysis techniques. In this case addi-
tional age groups have been evaluated. In our population, the
optimum cost-effectiveness was reached at 55 years and older
(see Figure 2), suggesting that this might be a better starting point
than the recommended 50 years. Review of the data in other cost-
effectiveness reports supports our findings. We chose to target 55
to 69-year-olds as the ‘base program’ because, from an economic
point of view, this represented the minimum program the Aus-
tralian Government could introduce. Review of the final results
(see Table 4) and discussion with the CSG Working Group iden-
tified targeting 55 to 74-year-olds as the optimum program, based
on current information. Inclusion of those 75 and over would de-
pend on further certainty about the compliance rates in that age
group. This cost-effectiveness profile may vary between coun-
tries, however, depending on population profiles, the epidemiol-
ogy of CRC, availability of health care resources and variations
in clinical practice, incentives to health care professionals and
institutions, health care system design, and acceptable threshold
values.31
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While the highest level of evidence, in terms of internal valid-
ity, has been used to model the point estimates, the sensitivity
analysis is more informative. The single point estimate provides
an indication of the efficacy of the program under ideal condi-
tions, such as an RCT. As such it provides an optimistic value for
the costs and consequences of the program, with costs and ICER
close to the lower limit and benefits close to the upper limit of the
uncertainty analysis. Therefore, reporting only the point estimate
may underestimate costs and the ICER. Furthermore, a single point
estimate suggests a certainty about the final values that does not
exist for many reasons, including the uncertainty around the origi-
nal study results, the effectiveness in less than ideal conditions
and their generalisability to the Australian context. Knowledge
of the range of potential benefits, costs and cost-effectiveness
from the sensitivity analysis (see Table 4) provides for more in-
formed decision-making both within a single program and across
programs. If the funding for a program is limited, it may be worth-
while to implement a conservative option that assumes the ex-
treme values of maximum cost, minimum benefits and lowest
anticipated ICER. It is often more feasible to extend the reach of
a program, if it proves to be more effective than anticipated, than
to reduce an existing program.
The sensitivity analysis has further implications for policy be-
cause it provides an indication of the main drivers for the costs
and consequences of the program, and some of these will hope-
fully be explored in the current pilot studies. The positivity of the
FOBT influences both cost and cost-effectiveness. The newer
generation of immunochemical tests that are specific for human
haemoglobin may reduce costs even further. A Japanese study
that compared the two methods showed that the immunochemical
test was three times as cost-effective as the guaiac tests.32
The implementation of an evidence-based policy is often de-
pendent on other factors in addition to the cost-effectiveness of
the program.33 As part of this study, the CSG Working Party uti-
lised the Program Budgeting and Marginal Analysis (PBMA)
approach to identify broader dimensions of benefit that might
affect resource choices, in addition to the reported ICERs. The
additional factors considered were ‘public health significance’,
‘equity’, ‘acceptability to stakeholders’ and ‘feasibility of options
for change’ to Australia’s cancer control strategy.13,14 CRC is an
important public health issue worldwide. Special action may be
required to encourage participation for disadvantaged groups such
as the Indigenous population, low socio-economic groups, those
from non-English speaking backgrounds, and rural residents.
Recent reports from the United States, for example, show CRC
screening rates tend to be lower in African Americans and
Hispanics, in groups with lower education, and in those lacking
insurance cover or a usual source of care.34,35
Acceptability to the main stakeholders will affect the partici-
pation rates, which is one of the major influential factors, and
this may be an issue not only for different age groups but also for
many disadvantaged groups. The acceptability of a CRC screen-
ing program to consumers, for example, needs to be established.
Medical practitioners will need to be convinced of the efficacy
and quality assurance aspects of the program if they are to
encourage participation. In Australia, there are sufficient well-
qualified colonoscopists,14,36 but their uneven distribution across
the nation may affect the feasibility of the program. The value of
commencing the program at a different age to breast cancer screen-
ing (currently 50 years) may have to be weighed against com-
mencing screening at too early an age. The risk is that this may
lead to non-compliance in later years when the likelihood of dis-
ease is higher.32 Consideration of these influential factors would
contribute to a more successful and equitable program.
As this study was part of a larger priority-setting exercise, we
can compare screening for CRC cancer with other cancer control
options. It is more costly and less cost effective than the primary
prevention options shown in Table 6 that were evaluated that may
be cost neutral or may even save money.13,14 On the other hand,
the program is expected to have a similar cost-effectiveness to the
current cervical cancer screening and breast cancer screening pro-
grams.7,8,10
Our study differs from previously published cost-effectiveness
studies in several respects. The main difference is the comparison
of the age group at which to start screening. The risk of develop-
ing CRC rises substantially from about the age of 50 and this may
be why a starting age of 50 years is often recommended. Many of
the economic analyses used mathematical simulation methods to
model a cohort of 50-year-olds, but unfortunately did not provide
information on screening at different age groups. Gyrd-Hansen8
modelled six different screening programs. Extrapolation of their
data demonstrates minimal health benefit and high costs for in-
clusion of the 50 to 54-year-olds, similar to our findings. Eddy37
showed this effect when comparing screening starting at 40 years
with 50 years. The anticipated health gain is very small but the
costs are almost double. Previous Australian studies used a model
based on an artificial cohort of 50-year-olds38 or the population
in the Minnesota study.23 Our use of a cross-sectional model has
enabled the comparison on an aggregate level of different sub-
groups, such as age in this case.
The comprehensiveness of the cost analysis, with separate re-
porting of both ‘gross costs’ and ‘net costs’ estimates, should also
be noted. This knowledge is important for the decision-making
process. The gross costs include the infrastructure costs of the
program and they provide the perspective of the CRC Screening
Program itself. The net costs, on the other hand, incorporate the
long-term costs and potential savings to the health system over-
all. Recovery of these costs/savings is not a forgone conclusion
and may depend on several practical and theoretical considera-
tions that include workforce restructuring, management policies,
political acceptability, professional interests and public reaction.
We did not consider the costs of future medical care unrelated to
colorectal cancer, which will occur because of the decrease in
premature mortality. Inclusion of these costs remains controver-
sial.30,31
Conclusion
The findings of this study have a number of policy implica-
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tions for countries recommending or considering implementing
screening programs for CRC. If less than $50,000 per DALY is
used as the yardstick for acceptable cost-effectiveness, then a bi-
ennial population-screening program using FOBT provides value-
for-money, particularly if screening starts at the age of 55 rather
than the most commonly advocated age of 50. In this age of screen-
ing, it is important that policy makers be mindful of the influen-
tial factors driving costs and consequences and include appropriate
incentives to control or modify these factors. This could include
disincentives if there is potential for provider-induced demand.
Pilot programs provide better information on important facets
of the program in the local setting. If pilot programs are part of a
staged approach to implementation, careful consideration should
be given to the age range for screening. Investigation of age and
the other influential factors in the pilot program is recommended
to confirm the findings of this modelling exercise before imple-
menting a full national program.
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